Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
30th January 2020 | Edward F Smith | 2,380 | Open or private sale | $2.05 | $4,879.00 |
10th January 2020 | Scott Braunstein | 26,500 | Grant/award etc. | $0.00 | |
31st December 2019 | Scott Braunstein | 31,780 | Grant/award etc. | $0.00 | |
13th December 2019 | Scott Braunstein | 100,000 | Open or private purchase | $1.25 | $125,000.00 |
29th May 2019 | Scott Braunstein | 4,967 | Grant/award etc. | $0.00 | |
16th May 2019 | Edward F Smith | 24,211 | Open or private sale | $5.03 | $121,781.33 |
18th March 2019 | Christopher Michael Cashman | 31,662 | Exercise of derivative | $1.04 | $32,928.48 |
29th January 2019 | Edward F Smith | 2,492 | Open or private sale | $3.06 | $7,625.52 |
28th January 2019 | Christopher Michael Cashman | 8,142 | Open or private sale | $3.13 | $25,484.46 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw in 2003.
12th February 2021